PapersFlow Research Brief

Health Sciences · Medicine

Metal complexes synthesis and properties
Research Guide

What is Metal complexes synthesis and properties?

Metal complexes synthesis and properties is the research area that designs, prepares, and characterizes coordination compounds—especially platinum-group and other transition-metal complexes—while relating their structures and physicochemical behaviors to biological interactions and therapeutic performance in oncology.

The literature cluster comprises 142,425 works focused on platinum-based cancer chemotherapy, including mechanisms of action, resistance, and toxicity, alongside the development of new metal complexes and their DNA interactions. "Cisplatin in cancer therapy: Molecular mechanisms of action" (2014) is a highly cited mechanistic anchor for how a prototypical platinum drug exerts anticancer effects. Foundational coordination-chemistry structure–property frameworks used across this area include "Relationships between the carbon-oxygen stretching frequencies of carboxylato complexes and the type of carboxylate coordination" (1980) and the crystallographic/spectroscopic study "Synthesis, structure, and spectroscopic properties of copper(II) compounds containing nitrogen–sulphur donor ligands; the crystal and molecular structure of aqua[1,7-bis(N-methylbenzimidazol-2′-yl)-2,6-dithiaheptane]copper(II) perchlorate" (1984).

Topic Hierarchy

100%
graph TD D["Health Sciences"] F["Medicine"] S["Oncology"] T["Metal complexes synthesis and properties"] D --> F F --> S S --> T style T fill:#DC5238,stroke:#c4452e,stroke-width:2px
Scroll to zoom • Drag to pan
142.4K
Papers
N/A
5yr Growth
2.3M
Total Citations

Research Sub-Topics

Why It Matters

Metal-complex synthesis and property characterization directly affects how anticancer agents are designed, formulated, and assessed for efficacy and safety. Dasari and Tchounwou’s "Cisplatin in cancer therapy: Molecular mechanisms of action" (2014) consolidates mechanistic knowledge that guides the design of next-generation platinum and non-platinum complexes intended to preserve anticancer activity while addressing resistance and toxicity. Kèlland’s "The resurgence of platinum-based cancer chemotherapy" (2007) frames why platinum drugs remain central to oncology and why new coordination compounds continue to be pursued as therapeutics. Delivery and biodistribution constraints are also central: Maeda et al.’s "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review" (2000) explains how tumor vascular permeability can be leveraged for macromolecular or carrier-based delivery strategies, which is relevant when metal complexes are incorporated into larger constructs. Materials platforms can further change pharmacology and local exposure; Horcajada et al.’s "Metal–Organic Frameworks in Biomedicine" (2011) surveys MOFs as biomedical carriers, providing a concrete route by which metal-containing frameworks can be engineered for biomedical use. Quantitative evaluation of combination regimens that include metal-based drugs is supported by Chou’s "Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies" (2006), which is widely used to distinguish synergy from antagonism in multi-drug oncology studies.

Reading Guide

Where to Start

Start with Dasari and Tchounwou’s "Cisplatin in cancer therapy: Molecular mechanisms of action" (2014) because it provides the clearest oncology-centered map from coordination chemistry to cellular mechanism, resistance, and toxicity for a canonical metal drug.

Key Papers Explained

Mechanistic motivation begins with "The resurgence of platinum-based cancer chemotherapy" (2007), which explains why platinum drugs remain central and why new complexes are sought. "Cisplatin in cancer therapy: Molecular mechanisms of action" (2014) then links platinum coordination chemistry to biological outcomes, giving a template for evaluating new metal complexes. Core structure–property tools that generalize beyond platinum include "Relationships between the carbon-oxygen stretching frequencies of carboxylato complexes and the type of carboxylate coordination" (1980) and Addison et al.’s "Synthesis, structure, and spectroscopic properties of copper(II) compounds containing nitrogen–sulphur donor ligands; the crystal and molecular structure of aqua[1,7-bis(N-methylbenzimidazol-2′-yl)-2,6-dithiaheptane]copper(II) perchlorate" (1984), which exemplify how coordination environment controls stability and spectra. Delivery and formulation considerations connect via "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review" (2000), "Introduction and General Overview of Cyclodextrin Chemistry" (1998), and "Metal–Organic Frameworks in Biomedicine" (2011), which together span tumor transport principles, host–guest formulation chemistry, and porous-carrier architectures. Quantitative evaluation of multi-agent regimens is anchored by "Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies" (2006).

Paper Timeline

100%
graph LR P0["A simple, rapid, and sensitive D...
1980 · 5.0K cites"] P1["Relationships between the carbon...
1980 · 5.0K cites"] P2["Synthesis, structure, and spectr...
1984 · 9.2K cites"] P3["Introduction and General Overvie...
1998 · 4.8K cites"] P4["Tumor vascular permeability and ...
2000 · 6.4K cites"] P5["Theoretical Basis, Experimental ...
2006 · 5.0K cites"] P6["Cisplatin in cancer therapy: Mol...
2014 · 5.3K cites"] P0 --> P1 P1 --> P2 P2 --> P3 P3 --> P4 P4 --> P5 P5 --> P6 style P2 fill:#DC5238,stroke:#c4452e,stroke-width:2px
Scroll to zoom • Drag to pan

Most-cited paper highlighted in red. Papers ordered chronologically.

Advanced Directions

Advanced work often combines (i) mechanistic benchmarking against the cisplatin paradigm in "Cisplatin in cancer therapy: Molecular mechanisms of action" (2014), (ii) tunable delivery informed by "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review" (2000), and (iii) platform-based control of exposure and release as discussed in "Metal–Organic Frameworks in Biomedicine" (2011). A practical frontier is integrating rigorous structure–property inference (e.g., "Relationships between the carbon-oxygen stretching frequencies of carboxylato complexes and the type of carboxylate coordination" (1980)) with standardized combination-therapy evaluation ("Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies" (2006)) to prioritize candidates for translational testing.

Papers at a Glance

# Paper Year Venue Citations Open Access
1 Synthesis, structure, and spectroscopic properties of copper(<... 1984 Journal of the Chemica... 9.2K
2 Tumor vascular permeability and the EPR effect in macromolecul... 2000 Journal of Controlled ... 6.4K
3 Cisplatin in cancer therapy: Molecular mechanisms of action 2014 European Journal of Ph... 5.3K
4 Theoretical Basis, Experimental Design, and Computerized Simul... 2006 Pharmacological Reviews 5.0K
5 A simple, rapid, and sensitive DNA assay procedure 1980 Analytical Biochemistry 5.0K
6 Relationships between the carbon-oxygen stretching frequencies... 1980 Coordination Chemistry... 5.0K
7 Introduction and General Overview of Cyclodextrin Chemistry 1998 Chemical Reviews 4.8K
8 The resurgence of platinum-based cancer chemotherapy 2007 Nature reviews. Cancer 4.6K
9 Determination of the base composition of deoxyribonucleic acid... 1962 Journal of Molecular B... 4.1K
10 Metal–Organic Frameworks in Biomedicine 2011 Chemical Reviews 4.0K

In the News

Code & Tools

Recent Preprints

Significance of Nano Transition Metal Complexes as ...

mdpi.com Preprint

Metal complexes have been utilized in medicine for thousands of years in various ways, with positive benefits. They are well recognized as delivery and diagnostic agents with anti-infective, antimi...

A manganese(I) complex with a 190 ns metal-to-ligand charge transfer lifetime

Aug 2025 nature.com Preprint

Precious metal complex photosensitizers, e.g. based on ruthenium(II) or iridium(III) with 4d6 and 5d6 electron configuration, respectively, possess strong visible light absorbance and long triplet ...

Ligand substituents modulate excited-state lifetime and energy-transfer reactivity in Cu(i) photosensitizers supported by salicylaldimine and isocyanide ligands

Oct 2025 osti.gov Preprint

ligand design in tuning the excited-state properties of this new class of copper-based photosensitizers. Results and discussion Synthesis The synthesis of the three-coordinate Cu(I) complexes Cu1–C...

Light-mediated CO release from a tricarbonyl manganese(i) complex with a bidentate quinoxaline ligand

Aug 2025 pubs.rsc.org Preprint

2. Results and discussion 2.1. Synthesis and structural characterization Scheme 1 illustrates that reacting o-phenylene diamine with 2- acetylpyridine in methanol, acidied with drops of glacial ac...

Synthesis and coordination behaviour of a protic phosphinoferrocene amidine

Aug 2025 pubs.rsc.org Preprint

A phosphinoferrocene amidine Ph2PfcNQCHNHiPr (1; fc = ferrocene-1,10-diyl) has been synthesised and studied as a new P,N-hybrid donor in group 10 metal complexes. Thus, reactions with metal dichlor...

Latest Developments

Recent developments in metal complexes synthesis and properties research include the advancement of solvent-free synthesis methods for Schiff base metal complexes (IntechOpen) and the use of robotic systems capable of synthesizing hundreds of metal complexes for drug discovery, such as antibiotics (phys.org). Additionally, AI models like DiffSyn are being developed to suggest new material syntheses, accelerating the discovery process (MIT News). Recent research also reports the synthesis of novel high-valent lanthanide complexes, such as praseodymium in the +5 oxidation state, and new intermetallic complexes with unique electronic structures (Nature, Nature Communications).

Frequently Asked Questions

What are “metal complexes” in the context of oncology drug research?

In oncology-focused coordination chemistry, metal complexes are coordination compounds whose biological activity depends on metal–ligand structure and reactivity, as exemplified by platinum drugs discussed in "Cisplatin in cancer therapy: Molecular mechanisms of action" (2014). This topic area also includes non-platinum complexes and carrier constructs, as surveyed in "Metal–Organic Frameworks in Biomedicine" (2011).

How are structure and bonding used to predict or rationalize metal-complex properties?

Coordination mode and ligand binding motifs are often inferred from spectroscopic and structural correlations, such as those compiled in "Relationships between the carbon-oxygen stretching frequencies of carboxylato complexes and the type of carboxylate coordination" (1980). Detailed structure–spectroscopy relationships for specific coordination environments are illustrated by "Synthesis, structure, and spectroscopic properties of copper(II) compounds containing nitrogen–sulphur donor ligands; the crystal and molecular structure of aqua[1,7-bis(N-methylbenzimidazol-2′-yl)-2,6-dithiaheptane]copper(II) perchlorate" (1984).

How do researchers connect metal complexes to DNA interactions and DNA-focused assays?

DNA interaction is central to platinum chemotherapy, and mechanistic framing is summarized in "Cisplatin in cancer therapy: Molecular mechanisms of action" (2014). DNA quantification and characterization methods frequently used alongside metal–DNA studies include "A simple, rapid, and sensitive DNA assay procedure" (1980) and "Determination of the base composition of deoxyribonucleic acid from its thermal denaturation temperature" (1962).

Which concepts help explain why delivery systems can change the performance of metal-based therapeutics?

Tumor-selective accumulation and permeability concepts are reviewed in "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review" (2000), providing a rationale for macromolecular or carrier-associated delivery strategies. Host–guest chemistry used in formulation and solubilization is summarized in "Introduction and General Overview of Cyclodextrin Chemistry" (1998), and biomedical carrier architectures are discussed in "Metal–Organic Frameworks in Biomedicine" (2011).

How is synergy or antagonism evaluated when metal drugs are combined with other anticancer agents?

Combination effects are commonly quantified using the framework in "Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies" (2006). That framework supports standardized experimental design and interpretation of whether a metal-based agent enhances or diminishes the effect of a partner drug.

What is the current state of platinum-based chemotherapy within this broader metal-complex field?

Platinum drugs remain a central reference point for mechanism, resistance, and toxicity discussions, as synthesized in "Cisplatin in cancer therapy: Molecular mechanisms of action" (2014). The continued clinical and research relevance of platinum chemotherapy is contextualized in "The resurgence of platinum-based cancer chemotherapy" (2007).

Open Research Questions

  • ? Which specific coordination-chemistry design rules best predict when a new metal complex will retain anticancer activity while reducing the resistance and toxicity patterns emphasized in "Cisplatin in cancer therapy: Molecular mechanisms of action" (2014)?
  • ? How can carrier strategies grounded in the permeability principles reviewed in "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review" (2000) be systematically matched to metal-complex speciation and stability to improve tumor exposure without increasing off-target burden?
  • ? Which measurable structural or spectroscopic descriptors—such as those discussed in "Relationships between the carbon-oxygen stretching frequencies of carboxylato complexes and the type of carboxylate coordination" (1980)—most reliably translate across different metal centers to predict biological reactivity relevant to oncology?
  • ? How can MOF-based biomedical platforms surveyed in "Metal–Organic Frameworks in Biomedicine" (2011) be engineered to control metal release or presentation while maintaining biocompatibility and reproducibility needed for therapeutic development?
  • ? Which experimental designs and statistical criteria from "Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies" (2006) are most robust when one agent is a reactive metal complex whose speciation changes over time in biological media?

Research Metal complexes synthesis and properties with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Metal complexes synthesis and properties with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers